National Academies Press: OpenBook

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)

Chapter: Appendix 8: Hepatitis C

« Previous: Appendix 7: Helicobacter pylori
Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

APPENDIX 8
Hepatitis C

The hepatitis C virus (HCV) is the major cause of parenteral non-A, non-B hepatitis. A chronic infection is usually asymptomatic even when liver damage is seen in biopsy. Eventually, the chronic infection can lead to cirrhosis and hepatocellular carcinoma. The prevalence of HCV is significantly greater in intravenous-drug users than in blood donors. At least half of the patients who have previously been diagnosed with posttransfusion non-A, non-B hepatitis have tested positive for HCV antibodies. Some countries, such as Japan, have a higher frequency of HCV infection, which is reflected in the high frequency of hepatocellular carcinoma.

DISEASE BURDEN

Epidemiology

For the purposes of the calculations in this report, the committee estimated that there are 150,000 new infections with HCV every year in the United States. It is assumed that all new infections occur in people between 15 and 54 years of age.

See Appendix 28 for more information.

Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Disease Scenarios

For the purposes of the calculation in this report, the committee assumed that 30% of people with HCV infection experience only an acute and mild disease lasting approximately 2 weeks. The health utility index (HUI) associated with this illness is .9. It was assumed that 50% of people with HCV infection experience lifelong but very mild intermittent illness (HUI of .97). It was assumed that 7% of HCV infections lead to chronic hepatitis associated with a rapid, progressive course leading to death within 7 years of infection. The remaining 13% of HCV infections were associated with the mortality from cirrhosis and liver failure 25 years after infection and cirrhosis and liver cancer 30 years after infection. See Table A8–1.

COST INCURRED BY DISEASE

Table A8–2 summarizes the health care costs incurred by HCV infections. For the purposes of the calculations in this report, it was assumed that a relatively small fraction of patients experiencing mild symptoms of acute hepatitis seek medical treatment. Hospitalization and related costs are included for a very few patients. For the 50% of patients with HCV who have lifelong, uncomplicated, mild hepatitis, it was assumed that, on average, 10% of these people see a physician for illness associated (but unrecognized in many cases) with the HCV infection.

HCV infections associated with a chronic course but leading to severe liver disease was associated with 20 and 30 years of treatment for low grade symptoms (diagnosed as HCV-related or not). 10% of patients visit a specialist every other year. The 4-year symptomatic phase was associated with quarterly specialist visits, 2 hospitalizations, and a biopsy (for 10% of the patients). The year spent in terminal cirrhosis, liver failure, or liver cancer was assumed to be associated with a hospitalization and monthly specialist visits.

The rapid, progressive course of HCV disease was assumed to be associated with antiviral medication, bimonthly specialist visits, 2 extensive diagnostics per year for 6 years, and 1 hospitalization during that time period. The final year of life was assumed to be associated with hospitalization and monthly visits to a specialist.

VACCINE DEVELOPMENT

The committee assumed that it will take 15 years until licensure of an HCV vaccine and that $360 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A8–1 Disease Scenarios for Hepatitis C Infection

 

No. of Cases

% of Cases

Committee HUI Values

Duration (years)

Total Cases (new symptomatic and asymptomatic infections)

150,000

 

Acute Hepatitis

45,000

30%

 

jaundice, malaise, etc.

 

0.90

0.0384 (2 weeks)

Chronic Hepatitis: Slow course—No complications

75,600

50%

 

low-grade symptoms

 

0.97

20.3164 (quality-adjusted life expectancy at onset). 43.3484 (unadjusted life expectancy at onset)

Chronic Hepatitis: Slow course—Cirrhosis to liver failure

3,780

3%

 

low-grade symptoms

 

0.97

20.0000

symptomatic phase

 

0.90

4.0000

terminal cirrhosis; liver failure

 

0.59

1.0000

premature death

 

0.00

12.3902 (quality-adjusted life expectancy at onset+25 years). 21.3870 (unadjusted life expectancy at onset+25 years)

Chronic Hepatitis: Slow course—Cirrhosis to carcinoma

15,120

10%

 

low-grade symptoms

 

0.97

30.0000

symptomatic phase

 

0.90

4.0000

terminal carcinoma

 

0.59

1.0000

premature death

 

0.00

8.7664 (quality-adjusted life expectancy at onset +35 years). 14.4048 (unadjusted life expectancy at onset+35 years)

Chronic Hepatitis: Rapid, progressive course

10,500

7%

 

liver failure: symptomatic

 

0.90

6.0000

liver failure: terminal

 

0.59

1.0000

premature death

 

0.00

18.5549 (quality-adjusted life expectancy at onset+7 years). 36.8422 (unadjusted life expectancy at onset+7 years)

Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A8–2 Health Care Costs Associated with Hepatitis C Infection

 

Duration (years)

% with Care

Cost per Unit

Units per Case

Form of Treatment (per year for chronic phases)

Acute Hepatitis

 

 

0.0384

20%

$50

2.0

physician a

0.0384

5%

$2,000

1.0

hospitalization

0.0384

5%

$100

2.0

physician b

0.0384

5%

$100

2.0

diagnostics b

0.0384

5%

$150

1.0

medication c

Chronic Hepatitis: Slow course—No complications

 

low-grade symptoms

43.3484

10%

$50

1.0

physician a

Chronic Hepatitis: Slow course—Cirrhosis to liver failure

 

low-grade symptoms

20.0000

10%

$100

0.5

physician visit

symptomatic phase

4.0000

100%

$100

4.0

physician b

 

4.0000

10%

$12,000

0.25

biopsy (1 in 4 years)

4.0000

100%

$5,000

0.5

hospitalization (1 in 2 years)

terminal cirrhosis; liver failure

1.0000

100%

$5,000

1.0

hospitalization

 

1.0000

100%

$100

12.0

physician b

Chronic Hepatitis: Slow course—Cirrhosis to carcinoma

 

low-grade symptoms

30.0000

10%

$100

0.5

physician a

symptomatic phase

4.0000

10%

$12,000

0.25

biopsy

 

4.0000

100%

$100

4.0

physician b

4.0000

100%

$5,000

0.5

hospitalization

terminal carcinoma

1.0000

100%

$5,000

1.0

hospitalization

 

1.0000

100%

$100

12.0

physician b

Chronic Hepatitis: Rapid, progressive course

 

liver failure: symptomatic

6.0000

100%

$150

12.0

medication c

 

6.0000

100%

$100

6.0

physician b

6.0000

100%

$1,000

2.0

diagnostics

6.0000

100%

$12,000

0.2

hospitalization

liver failure: terminal

1.0000

100%

$5,000

1.0

hospitalization

 

1.0000

100%

$100

12.0

physician b

Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

VACCINE PROGRAM CONSIDERATIONS

Target Population

For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is the annual birth cohort. It was assumed that 90% of the target population would utilize the vaccine.

Vaccine Schedule, Efficacy, and Costs

For the purposes of the calculations in this report, it was estimated that this vaccine would cost $50 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% efficacy were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for HCV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 110,000. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 41,000.

If a vaccine program for HCV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $ 180 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $67.9 million.

If a vaccine program for HCV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $720 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $360 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for a HCV vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present

Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

value of the cost per QALY gained is $5,000. If the target population was all 12-year-olds, the annualized present value of the cost per QALY gained is $3,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $7,400. If the target population was all 12-year-olds (assuming 50% utilization), the annualized present value of the cost per QALY gained is $4,000.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Bhandari BN, Wright TL. Hepatitis C: An Overview. Annual Review of Medicine 1995; 46:309–317.


Lemon SM, Brown EA. Hepatitis C Virus. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1474–1486.

Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 189
Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 190
Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 191
Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 192
Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 193
Suggested Citation:"Appendix 8: Hepatitis C." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 194
Next: Appendix 9: Herpes Simplex Virus »
Vaccines for the 21st Century: A Tool for Decisionmaking Get This Book
×
Buy Hardback | $72.95 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

  • Lessons to be learned from the polio experience.
  • Scientific advances that set the stage for new vaccines.
  • Factors that affect how vaccines are used in the population.
  • Value judgments and ethical questions raised by comparison of health needs and benefits.

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!